Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian, fallopian tube, or primary peritoneal cancer, collectively referred to as ovarian cancer, remains the deadliest type of gynaecological cancer. The most common and aggressive form is called high-grade serous ovarian cancer. The main purpose of this study is to understand whether an experimental study vaccine, CryptiVax-1001, is safe when administered to patients with high-grade serous ovarian cancer (HGSOC). The study vaccine is a cancer vaccine, which aims to delay or possibly prevent the cancer from coming back. However, as this is the first study of the vaccine in patients, the pri

Trial Details

NCT ID
NCT07665515
Phase
PHASE1
Sponsor
Epitopea Ltd
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • CryptiVax-1001
Locations (sample)
  • Cambridge, United Kingdom|52.2,0.11667
  • Edinburgh, United Kingdom|55.95206,-3.19648
  • Glasgow, United Kingdom|55.86515,-4.25763
  • Leeds, United Kingdom|53.79648,-1.54785
  • Leicester, United Kingdom|52.6386,-1.13169

Key Eligibility Criteria

  • Able to comprehend and are willing to sign the ICF and willing to follow the study procedures
  • Female, aged 18 years of age or older at the time of informed consent.
  • Histologically confirmed diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal carcinoma of high-grade serous histology or other h…
  • The FIGO 2014 stage III or IV disease at initial diagnosis.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →